![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HSH2D |
Gene summary for HSH2D |
![]() |
Gene information | Species | Human | Gene symbol | HSH2D | Gene ID | 84941 |
Gene name | hematopoietic SH2 domain containing | |
Gene Alias | ALX | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q96JZ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84941 | HSH2D | HCC1_Meng | Human | Liver | HCC | 1.10e-08 | -2.32e-02 | 0.0246 |
84941 | HSH2D | HCC2_Meng | Human | Liver | HCC | 7.12e-09 | 8.87e-02 | 0.0107 |
84941 | HSH2D | HCC1 | Human | Liver | HCC | 1.10e-03 | 1.13e+00 | 0.5336 |
84941 | HSH2D | HCC2 | Human | Liver | HCC | 5.39e-18 | 2.72e+00 | 0.5341 |
84941 | HSH2D | HCC5 | Human | Liver | HCC | 1.67e-16 | 1.37e+00 | 0.4932 |
84941 | HSH2D | S028 | Human | Liver | HCC | 1.24e-05 | 2.83e-01 | 0.2503 |
84941 | HSH2D | S029 | Human | Liver | HCC | 1.54e-04 | 4.01e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSH2D | SNV | Missense_Mutation | novel | c.347N>T | p.Pro116Leu | p.P116L | Q96JZ2 | protein_coding | deleterious(0.04) | benign(0.022) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSH2D | SNV | Missense_Mutation | novel | c.850N>C | p.Lys284Gln | p.K284Q | Q96JZ2 | protein_coding | deleterious(0.02) | benign(0.122) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HSH2D | SNV | Missense_Mutation | rs770936437 | c.133N>A | p.Glu45Lys | p.E45K | Q96JZ2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSH2D | SNV | Missense_Mutation | novel | c.343N>C | p.Glu115Gln | p.E115Q | Q96JZ2 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSH2D | SNV | Missense_Mutation | novel | c.97G>C | p.Glu33Gln | p.E33Q | Q96JZ2 | protein_coding | tolerated(0.15) | benign(0.099) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSH2D | SNV | Missense_Mutation | novel | c.697C>T | p.Leu233Phe | p.L233F | Q96JZ2 | protein_coding | tolerated(0.06) | possibly_damaging(0.585) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HSH2D | SNV | Missense_Mutation | novel | c.581N>G | p.Ser194Cys | p.S194C | Q96JZ2 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-A5-A2K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
HSH2D | SNV | Missense_Mutation | rs368010020 | c.887N>T | p.Ser296Leu | p.S296L | Q96JZ2 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HSH2D | SNV | Missense_Mutation | novel | c.552N>T | p.Lys184Asn | p.K184N | Q96JZ2 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
HSH2D | SNV | Missense_Mutation | novel | c.379N>A | p.Gln127Lys | p.Q127K | Q96JZ2 | protein_coding | deleterious(0.01) | possibly_damaging(0.674) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |